Synaptic dysfunction represents one of the earliest and most critical hallmarks of neurodegenerative diseases, preceding overt neuronal death by years or even decades[1]. The synapse, the fundamental unit of neuronal communication, relies on a delicate balance of neurotransmitter release, receptor signaling, and synaptic plasticity mechanisms. In Alzheimer's disease (AD), Parkinson's disease (PD), and related disorders, this balance becomes progressively disrupted, leading to impaired neural circuitry and ultimately cognitive and motor decline[2].
The modern understanding of synaptic dysfunction extends beyond simple neurotransmitter depletion. Research has revealed that synaptic loss correlates more strongly with cognitive impairment than amyloid plaque or neurofibrillary tangle burden in AD[3]. Similarly, in PD, synaptic dysfunction precedes and likely drives the degeneration of dopaminergic neurons in the substantia nigra[4]. This recognition has shifted therapeutic strategies toward synapse-preserving approaches.
The synaptic vesicle cycle is a highly orchestrated process involving vesicle trafficking, docking, fusion, and recycling. Key proteins including synaptophysin, synaptotagmin, and SNARE complexes regulate each stage. In neurodegenerative diseases, multiple components of this cycle become impaired.
In Alzheimer's disease, amyloid-beta (Aβ) oligomers directly interact with synaptic terminals, disrupting synaptic vesicle cycling before causing broader neuronal dysfunction[5]. Studies demonstrate that Aβ oligomers bind to presynaptic terminals, reducing synaptic vesicle pool size and impairing neurotransmitter release probability[6]. The presynaptic protein synaptophysin shows reduced expression in AD brains, correlating with cognitive decline[7].
The postsynaptic density (PSD) contains scaffolding proteins, receptors, and signaling molecules essential for synaptic transmission and plasticity. In neurodegenerative diseases, the PSD undergoes significant remodeling that disrupts synaptic signaling.
PSD-95 (postsynaptic density protein of 95 kDa), a major scaffold protein, is depleted in early AD stages[8]. This loss impairs NMDA receptor signaling and disrupts synaptic plasticity mechanisms including long-term potentiation (LTP)[9]. Similarly, AMPA receptor trafficking is altered in both AD and PD, reducing synaptic responsiveness[10].
Synaptic function critically depends on precise calcium signaling. Calcium influx through voltage-gated calcium channels and NMDA receptors triggers neurotransmitter release and activates signaling cascades essential for plasticity. Dysregulated calcium homeostasis represents a common pathogenic mechanism across neurodegenerative diseases[11].
In AD, amyloid-beta channels calcium-permeable pores in neuronal membranes, causing chronic calcium dysregulation[12]. This leads to activation of calcium-dependent proteases, phosphatases, and nucleases that degrade synaptic components. Similarly, mutations in alpha-synuclein alter synaptic calcium handling through interaction with the sarco/endoplasmic reticulum calcium-ATPase (SERCA)[13].
Alpha-synuclein is central to synaptic dysfunction in Parkinson's disease and dementia with Lewy bodies. This presynaptic protein normally regulates synaptic vesicle trafficking and neurotransmitter release[14]. In disease states, alpha-synuclein misfolds into toxic oligomers and fibrils that disrupt multiple aspects of synaptic function.
Alpha-synuclein oligomers directly impair synaptic vesicle cycling by binding to synaptic vesicles and altering their release properties[15]. Additionally, cell-to-cell transmission of alpha-synuclein aggregates spreads synaptic pathology throughout connected brain regions[16]. The presynaptic terminal thus represents a critical site where alpha-synuclein pathology initiates and propagates.
Beta-synuclein and gamma-synuclein are related proteins that may modulate alpha-synuclein toxicity. Beta-synuclein appears to have neuroprotective properties, potentially antagonizing alpha-synuclein aggregation[17].
Although traditionally studied in the context of microtubule stabilization and axonal transport, tau protein also localizes to synapses where it performs essential functions[18]. In Alzheimer's disease, pathological tau species accumulate at synapses, correlating with synaptic loss and cognitive decline[19].
Synaptic tau disrupts NMDA receptor trafficking and signaling, impairing LTP and contributing to memory deficits[20]. Tau also interacts with the postsynaptic scaffold, altering synaptic protein composition and function. Importantly, tau pathology spreads trans-synaptically, providing a mechanism for prion-like propagation of neurodegeneration[21].
Synaptic cell adhesion molecules including neurexin and neuroligin families mediate synapse development, maintenance, and plasticity. These proteins are increasingly recognized as vulnerable to neurodegenerative processes[22].
In AD, amyloid-beta disrupts neurexin-neuroligin signaling, contributing to synaptic loss[22:1]. Similarly, alpha-synuclein interacts with synaptic adhesion molecules, altering synapse structure and function. Genetic variants in neuroligin genes have been associated with increased risk for neurodegenerative diseases[23].
Synaptic loss is the strongest pathological correlate of cognitive impairment in AD[24]. Multiple mechanisms contribute to synaptic failure:
The cholinergic system, critical for attention and memory, shows early vulnerability in AD. Choline acetyltransferase activity declines, reducing acetylcholine synthesis. Presynaptic vesicular acetylcholine transporter expression also decreases, impairing neurotransmitter packaging[29].
In PD, synaptic dysfunction occurs both in the dopaminergic system and throughout the brain, contributing to motor and non-motor symptoms[30]. Key mechanisms include:
The striatum, receiving dopaminergic input from the substantia nigra, shows particular vulnerability. Synaptic terminals of dopaminergic neurons in the striatum (the striosomal compartment) exhibit early alpha-synuclein pathology and functional impairment[34].
Synaptic dysfunction also occurs in ALS, affecting both upper and lower motor neurons[35]. TDP-43 pathology, the hallmark of most ALS cases, disrupts synaptic function through multiple mechanisms:
In frontotemporal dementia and related disorders, synaptic dysfunction contributes to the characteristic behavioral and cognitive changes[39]. TDP-43 and FUS pathologies disrupt synaptic RNA metabolism, while tau pathology affects synaptic plasticity similarly to AD[40].
Preserving synaptic function represents a major therapeutic goal. Several approaches show promise:
Current symptomatic treatments partially address synaptic dysfunction:
Synaptic proteins in cerebrospinal fluid (CSF) serve as biomarkers for synaptic degeneration[48]:
These biomarkers enable earlier diagnosis and tracking of disease progression, as synaptic dysfunction precedes clinical symptoms by years.
Synaptic dysfunction represents a central pathological feature across neurodegenerative diseases, manifesting through disrupted neurotransmitter release, impaired receptor signaling, and loss of synaptic plasticity. The synapse serves as both a target of pathological protein aggregates and a vehicle for their spread throughout the brain. Understanding and targeting synaptic mechanisms offers hope for therapies that could preserve neural circuitry and function before irreversible neuronal loss occurs.
Synapses are extraordinarily energy-demanding structures, requiring constant ATP generation to maintain ion gradients, power synaptic vesicle cycling, and support plasticity mechanisms[52]. The presynaptic terminal contains numerous mitochondria that supply this energy, and mitochondrial dysfunction profoundly impacts synaptic function[53].
In neurodegenerative diseases, multiple mitochondrial defects converge on synaptic failure:
Mitochondrial fission and fusion dynamics critically regulate synaptic function. Fission generates new mitochondria for synaptic delivery, while fusion enables mitochondrial quality control through mixing of matrix components[57]. In neurodegeneration, these processes become imbalanced:
The PINK1-Parkin pathway, critical for mitophagy, is disrupted in PD. PINK1 mutations impair mitochondrial quality control, leading to accumulation of damaged mitochondria at synapses[61]. Similarly, CHCHD10 mutations cause mitochondrial dysfunction and ALS/FTD[62].
Synaptic vesicles must be transported from the cell body to presynaptic terminals via microtubule-based transport. This process depends on motor proteins including kinesins and dynein, regulated by tau protein and other microtubule-associated proteins[63].
In neurodegeneration, axonal transport becomes impaired through multiple mechanisms:
The result is synaptic vesicle depletion and impaired neurotransmitter release. Importantly, axonal transport defects occur early in disease pathogenesis, preceding overt neuronal loss[67].
LTP and LTD represent the cellular basis of learning and memory. These forms of synaptic plasticity require precise calcium signaling, NMDA receptor activation, and downstream signaling cascades that become disrupted in neurodegeneration[68].
In AD, multiple mechanisms impair LTP:
Similarly, LTD is enhanced in neurodegeneration, favoring synaptic weakening and elimination[72]. This imbalance between LTP and LTD contributes to cognitive decline.
neurons respond to altered activity through homeostatic scaling—global adjustments in synaptic strength that maintain circuit stability[73]. This compensatory mechanism becomes dysregulated in neurodegenerative diseases:
Beyond functional plasticity, synapses undergo structural remodeling including spine formation, enlargement, and elimination[77]. In neurodegeneration:
The brain-derived neurotrophic factor (BDNF) pathway, essential for structural plasticity, is impaired in both AD and PD[81].
Microglia actively prune synapses during development and adulthood, a process that becomes dysregulated in neurodegeneration[82]. In AD and PD:
Astrocytes regulate synaptic function through multiple mechanisms including neurotransmitter clearance, ion homeostasis, and metabolic support[86]. In neurodegeneration:
Large-scale proteomic studies have identified hundreds of synaptic proteins altered in neurodegenerative diseases[90]. These datasets reveal:
Genetic studies have identified variants in synaptic genes associated with neurodegenerative disease risk[94]:
Optogenetics enables precise control of synaptic activity to probe disease mechanisms[97]. Recent studies using channelrhodopsin to restore synaptic activity show:
Synaptic dysfunction represents a unifying pathological theme across neurodegenerative diseases, from early presymptomatic stages through advanced disease. The complex interplay between pathological protein aggregates, impaired calcium homeostasis, mitochondrial dysfunction, and glial responses creates a multifactorial assault on synaptic integrity. While current treatments provide only symptomatic relief, emerging disease-modifying approaches targeting synaptic preservation offer hope for therapies that could maintain neural circuit function long before irreversible neuronal loss occurs.
Early diagnosis through synaptic biomarkers, combined with targeted interventions that preserve synaptic structure and function, represents the most promising avenue for neurodegenerative disease treatment. As our understanding of synaptic mechanisms continues to advance, the synapse remains both the most vulnerable target and the most promising therapeutic focus in the fight against these devastating disorders.
Masliah E, et al. Synaptic and cognitive deficits in an Alzheimer's disease model. Neurobiology of Disease. 2001. ↩︎
Selkoe DJ. Alzheimer's disease is a synaptic failure. Science. 2002. ↩︎
Terry RD, et al. Synaptic loss in Alzheimer's disease and other dementias. Neurology. 1989. ↩︎
Subramaniam SR, et al. 'Targeting Parkinson''s disease: the alpha-synuclein problem'. Neurobiology of Disease. 2016. ↩︎
Wang Q, et al. Amyloid-beta oligomers and synaptic dysfunction. Neurobiology of Aging. 2007. ↩︎
Chen L, et al. Amyloid-beta and synaptic activity. Journal of Neuroscience. 2000. ↩︎
Masliah E, et al. Synaptic pathology in Alzheimer's disease. Annals of Neurology. 1991. ↩︎
Sun Q, et al. Postsynaptic density protein 95 in Alzheimer's disease. Brain Research. 2003. ↩︎
Roselli F, et al. Soluble amyloid beta peptides disrupt synaptic plasticity. Cell. 2005. ↩︎
Liu J, et al. AMPA receptor trafficking in neurodegenerative diseases. Neurology. 2012. ↩︎
Bezprozvanny I, Mattson MP. Neuronal calcium mishandling. Trends in Neurosciences. 2008. ↩︎
Demuro A, et al. Calcium dysregulation in Alzheimer's disease. Cell Calcium. 2010. ↩︎
Wang L, et al. Alpha-synuclein and calcium homeostasis. Cell Calcium. 2013. ↩︎
Burré J, et al. Alpha-synuclein in synaptic function. Neuron. 2015. ↩︎
Scott D, et al. Alpha-synuclein and synaptic vesicle dysfunction. Neurobiology of Disease. 2012. ↩︎
Deshpande A, et al. Synaptic propagation of alpha-synuclein pathology. Acta Neuropathologica. 2016. ↩︎
Windisch M, et al. Beta-synuclein and neuroprotection. Journal of Neural Transmission. 2002. ↩︎
Ittner LM, et al. Tau in physiology and pathology. Nature Reviews Neuroscience. 2010. ↩︎
Mukaetova-Ladinska EB, et al. Synaptic tau pathology in Alzheimer's disease. Brain. 2009. ↩︎
Ittner A, et al. Tau and NMDA receptor signaling in synapses. Proceedings of the National Academy of Sciences. 2010. ↩︎
Liu L, et al. Trans-synaptic spread of tau pathology. Neuron. 2012. ↩︎
Cissé M, et al. Receptor for advanced glycation end products in synaptic dysfunction. Journal of Neuroscience. 2011. ↩︎ ↩︎
Sudhof TC. Autism-associated neuroligin mutations. Science. 2015. ↩︎
DeKosky ST, Scheff SW. Synapse loss in Alzheimer's disease. Neurology. 1990. ↩︎
Shankar GM, et al. Amyloid-beta protein dimers isolated directly from Alzheimer's brains. Nature. 2008. ↩︎
Ittner LM, Götz J. 'Amyloid-beta and tau: the pushing and pulling of Alzheimer''s disease'. Cell. 2011. ↩︎
Markesbery WR. Oxidative stress hypothesis in Alzheimer's disease. Free Radical Biology and Medicine. 1997. ↩︎
Heneka MT, et al. Neuroinflammation in Alzheimer's disease. Lancet Neurology. 2015. ↩︎
Schliebs R, Arendt T. Cholinergic system in Alzheimer's disease progression. Journal of Alzheimer's Disease. 2011. ↩︎
Calabresi P, et al. Synaptic dysfunction in Parkinson's disease. Lancet Neurology. 2016. ↩︎
Garcia-Reitböck P, et al. Synaptic alpha-synuclein pathology in Parkinson's disease. Brain. 2015. ↩︎
Brichta L, et al. Dopamine deficiency in Parkinson's disease. Movement Disorders. 2014. ↩︎
Van Laar VS, et al. Mitochondria, synaptic function, and neural connectivity. Annals of the New York Academy of Sciences. 2009. ↩︎
Crittenden JR, Graybiel AM. Basal ganglia-striosome circuits. Current Opinion in Neurobiology. 2011. ↩︎
Fogarty MJ, et al. Synaptic dysfunction in ALS. Brain Research. 2015. ↩︎
Prudencio M, et al. TDP-43 and ALS. Trends in Neurosciences. 2015. ↩︎
Zhang K, et al. TDP-43 and nucleocytoplasmic transport. Neuron. 2018. ↩︎
Bhardwaj R, et al. Autophagy in synaptic dysfunction. Autophagy. 2015. ↩︎
Rascovsky K, et al. Frontotemporal dementia. Brain. 2011. ↩︎
Irwin DJ, et al. 'Frontotemporal dementia: tauopathy and synapse loss'. Brain. 2016. ↩︎
Cummings J, et al. Alzheimer's disease drug development pipeline. Alzheimer's & Dementia. 2022. ↩︎
Weihofen A, et al. Alpha-synuclein immunotherapy. Science Translational Medicine. 2021. ↩︎
Wu Y, et al. Tau-targeted therapies for Alzheimer's disease. Nature Reviews Drug Discovery. 2022. ↩︎
Yang MH, et al. Synaptic protein kinase C activators. Neuropharmacology. 2017. ↩︎
Giacobini E. Cholinesterase inhibitors for Alzheimer's disease. CNS Drugs. 2002. ↩︎
Poewe W, et al. Parkinson's disease pathogenesis and treatment. Nature Reviews Disease Primers. 2021. ↩︎
McShane R, et al. Memantine for dementia. Cochrane Database of Systematic Reviews. 2022. ↩︎
Brinkmalm A, et al. Cerebrospinal fluid biomarkers for synaptic degeneration. Molecular Neurodegeneration. 2014. ↩︎
De Vos A, et al. Neurogranin as a synaptic biomarker in Alzheimer's disease. Journal of Alzheimer's Disease. 2015. ↩︎
Brinkmalm A, et al. SNAP-25 in cerebrospinal fluid. Molecular Neurodegeneration. 2014. ↩︎
Öhrfelt A, et al. Cerebrospinal fluid synaptotagmin-1 in neurodegenerative diseases. BMC Neurology. 2016. ↩︎
Attwell D, Laughlin SB. Energy budget for synaptic activity. Journal of Cerebral Blood Flow & Metabolism. 2001. ↩︎
Sheng ZH, Cai Q. Mitochondrial transport in neurons. Trends in Neurosciences. 2012. ↩︎
Schapira AH, et al. Mitochondrial complex I deficiency in Parkinson's disease. Lancet. 2014. ↩︎
Lin MT, Beal MF. Mitochondrial dysfunction and oxidative stress. Nature Neuroscience. 2006. ↩︎
Duchen MR. Mitochondria, calcium and excitotoxicity. Cell Calcium. 2012. ↩︎
Youle RJ, van der Bliek AM. Mitochondrial fission and fusion. Science. 2012. ↩︎
Itoh K, et al. Mitochondrial fission in neurodegeneration. Biochimica et Biophysica Acta. 2013. ↩︎
Chen H, Chan DC. Mitochondrial dynamics and inheritance. Human Molecular Genetics. 2007. ↩︎
Lin XC, et al. Mitophagy in synaptic dysfunction. Cell Death & Disease. 2021. ↩︎
Pickrell AM, Youle RJ. PINK1 and Parkin in mitochondrial quality control. Science. 2015. ↩︎
Bannwarth S, et al. CHCHD10 and mitochondrial disease. Brain. 2014. ↩︎
Hirokawa N, et al. Kinesin superfamily proteins and neuronal function. Nature Reviews Neuroscience. 2010. ↩︎
Mandelkow E, Mandelkow E. Tau in physiology and pathology. Trends in Cell Biology. 2006. ↩︎
Moran PM, et al. Amyloid-beta and axonal transport. Journal of Alzheimer's Disease. 2011. ↩︎
Stokin GB, et al. Axonal degeneration and impaired axonal transport. Neurology. 2005. ↩︎
Chevalier-Larsen E, Holzbaur EL. Axonal transport and neurodegenerative disease. Biochimica et Biophysica Acta. 2006. ↩︎
Bliss TV, Collingridge GL. LTP in the hippocampus. Nature. 1993. ↩︎
Lambert MP, et al. Amyloid-beta oligomer-induced synaptotoxicity. Proceedings of the National Academy of Sciences. 1998. ↩︎
Kim J, et al. Tau and synaptic plasticity. Neurobiology of Aging. 2012. ↩︎
Day M, et al. Postsynaptic density proteins in Parkinson's disease. Molecular Brain. 2013. ↩︎
Hsieh H, et al. AMPA receptor trafficking in synaptic plasticity. Learning & Memory. 2003. ↩︎
Turrigiano GG. 'The self-tuning neuron: synaptic scaling of excitatory synapses'. Cell. 2008. ↩︎
Petrache AL, et al. Homeostatic synaptic scaling in neurodegeneration. Cell Calcium. 2015. ↩︎
Palop JJ, Mucke L. Network excitability in Alzheimer's disease. Nature. 2010. ↩︎
Turrigiano G. Homeostatic plasticity in neural networks. Current Opinion in Neurobiology. 2017. ↩︎
Yuste R, Bonhoeffer T. Morphological changes in dendritic spines. Annual Review of Neuroscience. 2001. ↩︎
Blanpied TA, Ehlers MD. Spine architecture in brain disease. Nature Neuroscience. 2004. ↩︎
Bourne JN, Harris KM. Spine geometry and synapse ultrastructure. Synapse. 2012. ↩︎
Mukaetova-Ladinska EB, et al. Synaptic proteins in Alzheimer's disease. Brain Research. 2009. ↩︎
Allen SJ, et al. 'BDNF: from neurodegenerative disease to cognitive function'. Trends in Pharmacological Sciences. 2011. ↩︎
Paolicelli RC, et al. Microglial phagocytosis in synaptic plasticity. Neuron. 2011. ↩︎
Hong S, et al. Microglia and synapse elimination. Science. 2016. ↩︎
Stevens B, et al. Complement and microglial synaptic pruning. Cell. 2007. ↩︎
Ulland TK, et al. TREM2 and microglial neurodegeneration. Cell. 2017. ↩︎
Araque A, et al. 'Tripartite synapses: glia-neuron communication'. Neuron. 1998. ↩︎
McKeage K, et al. Astrocytic glutamate transporters in disease. Nature Reviews Neuroscience. 2004. ↩︎
Kofuji P, Connors NC. Astrocytic potassium homeostasis. Current Opinion in Neurobiology. 2003. ↩︎
Pellerin L, Magistretti PJ. Astrocyte-neuron lactate shuttle. Proceedings of the National Academy of Sciences. 1994. ↩︎
Huganir RL, et al. Synaptic proteomics in brain disease. Neuron. 2013. ↩︎
Beach TG, et al. Synaptic protein expression in neurodegenerative disease. Journal of Neuropathology & Experimental Neurology. 2018. ↩︎
Galvin JE, et al. Synaptic proteins in Parkinson's disease brain. Annals of Neurology. 2000. ↩︎
Campion D, et al. Synaptic proteins as therapeutic targets. Nature Reviews Drug Discovery. 2020. ↩︎
Satake W, et al. SNCA variants and Parkinson's disease risk. Nature Genetics. 2009. ↩︎ ↩︎
Cruchaga C, et al. PLD3 variants and Alzheimer's disease. Nature. 2013. ↩︎
Van Deerlin VM, et al. TMEM106b and frontotemporal dementia. Nature. 2010. ↩︎
Boyden ES, et al. Millisecond-timescale optogenetic control. Nature Neuroscience. 2005. ↩︎
Royer S, et al. Optogenetic restoration of hippocampal memory. Nature. 2012. ↩︎
Zhang H, et al. Optogenetic stimulation rescues synaptic plasticity. Neurobiology of Learning and Memory. 2015. ↩︎